-
Neuronetics (STIM) Misses Q4 EPS by 1c ; Offers Guidance
-
Neuronetics reports preliminary Q4 revenue of $41.8 million
-
TRICARE West expands coverage for depression treatment to teens 15+
-
Neuronetics (STIM) Reports In-Line Q3 EPS ; Offers Guidance
-
Neuronetics signs exclusive three-year deal with Elite DNA Behavioral Health
-
Neuronetics (STIM) PT Raised to $324 at Stifel
-
New York Medicaid expands TMS therapy coverage for depression treatment
-
Neuronetics (STIM) PT Lowered to $7 at Canaccord Genuity
-
Neuronetics (STIM) Misses Q2 EPS by 7c ; Offers Guidance
-
Citizens JMP Reiterates Market Outperform Rating on Neuronetics (STIM)
-
Piper Sandler Highlights Top Medtech Picks and Catalyst-Rich Names
-
Neuronetics Inc. (STIM) to Join Russell 2000 and Russell 3000 Indexes
-
Neuronetics (STIM) Misses Q1 EPS by 2c ; Offers Guidance
-
North Carolina Passes House Bill 152, Mandates Health benefit Plans must cover TMS
-
Citizens JMP Reiterates Market Outperform Rating on Neuronetics (STIM)
-
Neuronetics (STIM) PT Raised to $8 at Canaccord Genuity
-
Neuronetics (STIM) Misses Q4 EPS by 9c ; Offers Guidance
-
Neuronetics Inc. (STIM) Prices 8M Share Offering at $2.25/sh
-
Neuronetics (STIM) Announces Launch of Underwritten Public Offering of Common Stock
-
Neuronetics Inc. (STIM) Provides Business Update and Issues 2025 Guidance
-
Neuronetics (STIM) Misses Q3 EPS by 21c; offers guidance
-
Neuronetics (STIM) Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
-
William Blair Downgrades Neuronetics (STIM) to Market Perform
-
Neuronetics (STIM) PT Lowered to $3 at Canaccord Genuity
-
Neuronetics (STIM) and Greenbrook TMS Announce Definitive Agreement to Merge
-
Neuronetics (STIM) Misses Q2 EPS by 6c ; Offers Guidance

